Article: Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease.(Conference news)(Clinical report)

Article: Medivation's Dimebon(TM) Maintains Statistically ...
PR Newswire;  June 11, 2007 ;     700+ words ... ... mild-to-moderate Alzheimer's disease. Dimebon produced an aggregate ... this study, I consider Dimebon one of the most promising Alzheimer's disease compounds ... clinical studies of Dimebon in Alzheimer's disease next year ...

Article: Medivation's Dimebon(TM) Phase 2 Trial Results to be ...
PR Newswire;  January 30, 2007 ;     700+ words ... ... 2 efficacy study of Dimebon(TM) in Alzheimer's disease will be ... treat mild to moderate Alzheimer's disease. Dimebon met all five efficacy ... currently evaluating Dimebon in clinical trials in both Alzheimer's and Huntington ...

Article: Medivation Announces First Patient Dosed in Phase II Trial with ...
Business Wire;  September 9, 2005 ;     700+ words ... ... U.S. and Europe covering the use of Dimebon to treat Alzheimer's disease and other neurological diseases ... Company's first product candidate is Dimebon(TM) for Alzheimer's disease. Dimebon is a small molecule that has a 20-year ...

Article: In Alzheimer's, Anatomy is not Destiny Dimebon ...
BIOWORLD Today;  July 18, 2008 ;     700+ words ... ... Medivation Inc.'s Dimebon for the treatment of Alzheimer's disease showed ... that could fight Alzheimer's found that Dimebon showed some promise ... conducted in Russia, Dimebon improved the cognitive ... and functioning of Alzheimer's patients, demonstrating ...

Article: Medivation's Dimebon(TM) Significantly Improved Daily ...
Health & Medicine Week;  April 28, 2008 ;     700+ words ... ... announced that Alzheimer's patients taking ... investigational drug Dimebon(TM) showed significant ... of therapy with Dimebon, Alzheimer's disease patients ... moderate AD. Dimebon improved the clinical course of Alzheimer's disease patients ...

Article: Medivation Announces Publication in The Lancet of Dimebon ...
PR Newswire;  July 17, 2008 ;     700+ words ... ... mild-to-moderate Alzheimer's disease treated with Dimebon experienced statistically ... findings are replicated, Dimebon could advance Alzheimer's treatment, offering ... pivotal Phase 3 study of Dimebon in Alzheimer's disease." About ...

Article: Medivation Announces Publication in the Lancet of Dimebon ...
Biotech Week;  July 30, 2008 ;     700+ words ... ... mild-to-moderate Alzheimer's disease treated with Dimebon experienced statistically ... findings are replicated, Dimebon could advance Alzheimer's treatment, offering ... pivotal Phase 3 study of Dimebon in Alzheimer's disease." Keywords ...